New hope or drawbacks: Will chronic kidney disease be treatable with small molecules in the near future?

Future Medicinal Chemistry

Volumn 4, Issue 3, 2012, Pages 269-271

  Merk, Daniel ^a   Schubert Zsilavecz, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

anti inflammatory drugs; bardoxolone; chronic kidney disease; Keap1 Nrf2

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BARDOXOLONE METHYL; CISPLATIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; OLEANOLIC ACID; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRANSCRIPTION FACTOR NRF2;

ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; EDITORIAL; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY PELVIS CANCER; LUNG CANCER; MUSCLE SPASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; SIDE EFFECT; WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID; RENAL INSUFFICIENCY, CHRONIC;

EID: 84858039867     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.182     Document Type: Editorial

References (14)

1. Nozomu T, Masayoshi Y. Treatment of metastatic renal cell carcinoma and renal pelvic cancer. Clin. Exp. Nephrol. 15, 331-338 (2011).
2. Thomas M, Cooper M. Bardoxolone improves kidney function in Type 2 diabetes. Nat. Rev. Nephrol. 7, 552-553 (2011).
3. Mathew A, Cunard R, Sharma K. Antifibrotic treatment and other new strategies for improving renal outcomes. Contrib. Nephrol. Basel 170, 217-227 (2011).
4. Pergola P, Raskin P, Toto R et al. Bardoxolone methyl and kidney function in CKD with Type 2 diabetes. N. Engl. J. Med. 365, 4 (2011).
5. Honda T, Hidenori Y, Chitra S et al. Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents. J. Med. Chem. 54, 1762-1778 (2011).
6. Rinaldi Tosi M, Bocanegra V, Manucha W, Lorenzo A, Vallés P. The Nrf2-Keap1 cellular defense pathway and heat shock protein 70 (Hsp70) response. Role in protection against oxidative stress in early neonatal unilateral ureteral obstruction (UUO). Cell Stress Chaperones 16, 57-68 (2011).
7. Van Laecke S, Rogacev K, Upadhyay A, Macmahon G, Pergola P. Bardoxolone methyl, chronic kidney disease and Type 2 diabetes. N. Engl. J. Med. 365, 18 (2011).
8. Honda T, Dinkova-Kostova A, David E et al. Synthesis and biological evaluation of 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4- ethynylimidazole. A novel and highly potent anti-inflammatory and cytoprotective agent. Bioorganic Med. Chem. Lett. 21, 2188-2191 (2011).
9. Sporn M, Liby K, Yore M et al. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J. Nat. Prod. 74, 537-545 (2011).
10. Liby K, Risingsong R, Royce D et al. Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prev. Res. 2, 1050-1058 (2009).
11. Liby K, Royce D, Williams R et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 67, 2414-2419 (2007).
12. Speranza G, Gutierrez M, Kummar S et al. Phase I study of the synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors. Cancer Chemother. Pharmacol. 69(2), 431-438 (2012).
13. Pergola P, Krauth M, Huff JW et al. Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD. Am. J. Nephrol. 33, 469-476 (2011).
14. Wu Q, Wang Y, Senitko M et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARg and HO-1. Am. J. Physiol. Renal. Physiol. 300, F1180-F1192 (2011).